EGFR and lung carcinoma: The global LUX-Lung 3 study evaluated afatinib versus pemetrexed/cisplatin and also showed significantly prolonged PFS with afatinib both overall (11.1 vs. 6.9 months; P = 0.001) and in patients with common (exon 19 deletions or L858R) EGFR mutations (13.6 vs. 6.9 months; P < 0.0001) by independent review; results also showed a significantly higher RR (56% vs. 23%; P = 0.001) and delayed worsening of lung cancer-related symptoms with afatinib 34–36.